Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia

Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Meeuse, Jan J., Sprenger, Herman G., van Assen, Sander, Leduc, Dominique, Daenen, Simon M.G.J., Arends, Jan P., van der Werf, Tjip S.
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2007
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876741/
https://www.ncbi.nlm.nih.gov/pubmed/18258054
http://dx.doi.org/10.3201/eid1312.061559
Descripción
Sumario:Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive cells. We report a patient in whom Rhodococcus equi infection developed after alemtuzumab therapy.

Ejemplares similares